The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pilot phase II study with docetaxel in combination with curcuminoids in patients with hormone-resistant prostate cancer (HRPC).
H. Mahammedi
No relevant relationships to disclose
E. Planchat
No relevant relationships to disclose
H. Cure
No relevant relationships to disclose
C. Barthomeuf
No relevant relationships to disclose
M. Bayet-Robert
No relevant relationships to disclose
M. Mouret-Reynier
No relevant relationships to disclose
C. Abrial
No relevant relationships to disclose
E. Thivat
No relevant relationships to disclose
M. Atger
No relevant relationships to disclose
L. Savareux
No relevant relationships to disclose
L. Guy
No relevant relationships to disclose
J. Goyard
No relevant relationships to disclose
P. J. M. Chollet
No relevant relationships to disclose
J. Nabholtz
No relevant relationships to disclose
X. Durando
No relevant relationships to disclose
J. Eymard
No relevant relationships to disclose